Genenta Science Rings the Closing Bell in Celebration of its IPO
ABOUT THIS EVENT
Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the treatment of cancers with a proprietary technology platform that allows the direct delivery of immunotherapeutic payloads within the tumor microenvironment, visits the Nasdaq MarketSite in Times Square.
In honor of the occasion, Dr Pierluigi Paracchi, Genenta Science CEO and Luigi Naldini Professor, Ph.D., M.D., Co-Founder & Executive Scientific Board Chairman, rings the Closing Bell.